First-line therapy choices for advanced EGFR-mutated lung cancer weigh survival gains against toxicity and access

A new narrative review published in Frontiers in Oncology maps out how first-line treatment decisions for advanced EGFR-mutated non-small cell lung cancer (NSCLC) have become a balancing act between efficacy, toxicity, and real-world feasibility, particularly in low- and middle-income countries such as Brazil. The review, authored by a Brazilian thoracic oncology group, synthesizes phase III trial evidence on three currently recommended first-line strategies: osimertinib monotherapy, amivantamab combined with lazertinib, and osimertinib plus platinum-pemetrexed chemotherapy. Its central message is that newer combination regimens extend survival but carry substantially heavier toxicity and treatment burdens, and that patient priorities must be integrated into therapeutic choices.

NSCLC accounts for 80 to 85 percent of lung cancer cases, affecting roughly 1.98 to 2.11 million people worldwide, and EGFR mutations are present in 32.3 percent of the world’s NSCLC patients. EGFR-mutated NSCLC occurs more frequently in women, never-smokers, and patients of Asian ancestry, and is characterized by a high propensity for central nervous system metastases. Around 40 percent of NSCLC patients present with distant metastases at diagnosis, and the estimated 5-year survival rate for metastatic EGFR-mutated disease remains very low, at 11 to 19 percent. The review focuses on the common sensitizing mutations, exon 19 deletions and L858R, which together account for over 80 percent of EGFR-mutated NSCLC, while excluding biologically distinct subgroups such as exon 20 insertions and atypical mutations.

The therapeutic landscape has shifted over two decades. First-generation EGFR tyrosine kinase inhibitors gefitinib and erlotinib were approved by the US Food and Drug Administration in 2003 and 2004 and by the Brazilian regulatory agency ANVISA in 2010 and 2006, respectively. Second-generation drugs afatinib and dacomitinib followed, with FDA approval in 2013 and 2018; ANVISA approved afatinib in 2016 but dacomitinib is not registered in Brazil. Third-generation agents were developed for better central nervous system penetration and activity against the T790M resistance mutation. Osimertinib, approved by the FDA in 2015 and ANVISA in 2018, has been the standard first-line therapy since 2018. Lazertinib was approved by the FDA in combination with amivantamab in 2024 and registered by ANVISA in 2025.

The efficacy data come from three landmark randomized trials. In the double-blind FLAURA trial, 556 treatment-naive patients with metastatic EGFR-mutated non-squamous NSCLC were randomized to osimertinib 80 mg daily or a first-generation EGFR-TKI. Osimertinib significantly improved progression-free survival, with a median of 18.9 months versus 10.2 months (hazard ratio 0.46), and overall survival, with a median of 38.6 months versus 31.8 months (hazard ratio 0.80). Among the 19 percent of participants with baseline CNS metastases, median CNS progression-free survival was 15.2 months versus 9.6 months, and the CNS objective response rate among patients with measurable baseline CNS lesions was 91 percent versus 68 percent.

The MARIPOSA trial compared amivantamab plus lazertinib against osimertinib in 1074 previously untreated patients assigned in a 2:2:1 ratio. Amivantamab was given intravenously weekly for the first four weeks and then every two weeks, while both oral agents were taken daily. The combination improved median progression-free survival to 23.7 months versus 16.6 months (hazard ratio 0.70), and updated analysis showed a statistically significant overall survival benefit, with a 3-year overall survival rate of 60 percent versus 51 percent (hazard ratio 0.75; p=0.005). Benefits extended to high-risk subgroups, including patients with detectable circulating tumor DNA, TP53 co-mutations, and liver metastases. Dual EGFR/MET blockade reduced the risk of CNS progression or death by approximately 42 percent compared with osimertinib, and CNS response rates were comparable between arms at roughly 83 to 85 percent versus 80 to 82 percent.

The FLAURA 2 trial randomized 557 patients to osimertinib plus pemetrexed with cisplatin or carboplatin for four cycles followed by maintenance, or to osimertinib alone. The combination improved median progression-free survival to 25.5 months versus 16.7 months (hazard ratio 0.62) and median overall survival to 47.5 months versus 37.6 months (hazard ratio 0.77). In the subgroup with CNS metastases, median progression-free survival was 24.9 months versus 13.8 months. ANVISA approved the osimertinib-chemotherapy combination in April 2024 for first-line treatment of locally advanced or metastatic EGFR-mutated NSCLC. Current NCCN guidelines preferentially recommend all three strategies as first-line options once an exon 19 deletion or L858R mutation is detected.

These efficacy gains come at a measurable toxicity cost. In FLAURA, grade 3 or above adverse events occurred in 31 percent of osimertinib patients versus 41 percent of first-generation TKI patients, with rash, diarrhea, and dry skin most common, and treatment-related deaths in less than 1 percent in both groups. In MARIPOSA, grade 3 or above events affected approximately 80 percent of amivantamab plus lazertinib patients versus 52 percent of osimertinib patients. Infusion-related reactions occurred in 63 percent of combination patients, venous thromboembolic events in 37 percent versus 9 percent, and treatment-related deaths in 3 percent versus less than 1 percent. Events leading to interruption, dose reduction, or discontinuation affected 83, 59, and 35 percent of combination patients, respectively. In FLAURA 2, grade 3 or above events occurred in 64 percent of combination patients versus 27 percent on monotherapy, with neutropenia and thrombocytopenia prominent during induction, and treatment-related deaths in approximately 2 percent versus less than 1 percent.

The burden extends beyond adverse event rates into prophylaxis, monitoring, and multidisciplinary care. Osimertinib monotherapy requires no standardized prophylactic medications, relying instead on risk-based monitoring including baseline and periodic electrocardiograms for patients at risk of QT prolongation. Amivantamab plus lazertinib demands far more: in the MARIPOSA protocol, prophylactic anticoagulation was mandatory during the first four months to mitigate the high venous thromboembolism rate, although routine universal anticoagulation is not mandatory in real-world practice under current labels. Dexamethasone before the first dose mitigates infusion reactions, and extensive dermatologic prophylaxis is recommended. Ongoing monitoring covers peripheral neuropathy, peripheral edema, hypoalbuminemia, ocular toxicities, pyogenic granuloma-like lesions, and anogenital ulcers. The chemotherapy combination adds antiemetic prophylaxis, hydration, and complete blood count monitoring, with nephrology, cardiology, dermatology, ophthalmology, and neurology involvement indicated for severe or complex toxicities.

Patient preference data add a decisive dimension. In a discrete choice experiment, lung cancer patients identified a therapy’s ability to reduce tumor-related symptoms such as pain, coughing, and shortness of breath as the most influential factor in treatment decisions. In a discrete-choice simulation involving patients with incurable solid tumors, 51 percent of participants would not accept any additional toxicity for any magnitude of progression-free or overall survival gain, prioritizing immediate quality of life. A recent cross-sectional survey found that patients, care partners, and physicians rate overall survival as the most important treatment attribute, but quality of life, ranked second by patients and care partners, was ranked only fourth by clinicians. The review notes that these general preference data provide a behavioral rationale for why many patients and clinicians prefer first-line osimertinib monotherapy, an oral option with a manageable toxicity profile and minimal hospital-bound monitoring burden, unless high-risk factors such as extensive baseline CNS or liver metastases warrant intensification.

Access disparities sharpen the dilemma in Brazil and comparable settings. Although ANVISA has approved next-generation treatments, the public system SUS has not incorporated third-generation TKIs or intensive combinations for first-line use, leaving public patients largely restricted to first-generation EGFR-TKIs, while private sector coverage is mandated by the National Supplementary Health Agency but remains heterogeneous. According to the SBOC consensus, osimertinib monotherapy is recognized as the preferred first-line standard of care in the Brazilian context, driven by oral feasibility, favorable safety, and broader reimbursement access. Molecular testing availability varies substantially across regions, with reference centers concentrated in major urban areas, and infrastructure for managing complex toxicities is concentrated in specialized centers. The authors conclude that the central challenge is no longer the lack of effective treatments but determining how to deploy them, and that optimal care will depend on aligning biological rationale, clinical evidence, patient values, and regional realities into personalized treatment strategies.

Subject of Research: First-line treatment strategies for advanced EGFR-mutated non-small cell lung cancer, weighing efficacy, toxicity, patient preferences, and access barriers in low- and middle-income countries

Article Title: Optimizing first-line therapy for advanced EGFR-mutated NSCLC: a patient-centered approach for low- and middle- income countries

Article References: Gelatti, A. C. Z., Mascarenhas, E., Harada, G., Mendes, S. V., & Cordeiro de Lima, V. C. (2026). Optimizing first-line therapy for advanced EGFR-mutated NSCLC: a patient-centered approach for low- and middle- income countries. Frontiers in Oncology, 16, Article 1940079. https://doi.org/10.3389/fonc.2026.1940079

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1940079

Keywords: EGFR-mutated NSCLC, first-line therapy, osimertinib, amivantamab, lazertinib, FLAURA trial, MARIPOSA trial, FLAURA 2 trial, patient preferences, toxicity, Brazil healthcare access, shared decision-making